Indo Borax Acquires 64.26% Stake in Kronox Lab for ₹246 Crore
Indo Borax & Chemicals Limited will acquire 64.26% of Kronox Lab Sciences Limited for ₹246.11 crore. The company will also launch a mandatory open offer for an additional 25.79% stake. The acquisition aims to diversify Indo Borax's portfolio and is expected within three months.
This is a material acquisition that significantly increases Indo Borax's stake in Kronox Lab Sciences Limited and involves a substantial financial outlay, which will likely have a significant impact on the company's future operations and financial performance.
The acquisition of a significant stake in another company and the subsequent open offer are strategic moves that are generally viewed positively by the market, indicating growth and expansion plans.
Indo Borax & Chemicals Limited has announced the approval of a share purchase agreement for the acquisition of 2,38,44,000 equity shares of Kronox Lab Sciences Limited. This represents 64.26% of the share capital of Kronox Lab Sciences Limited, acquired from its promoters, Mr. Ketan Vinodchandra Ramani, Mr. Pritesh Vinodchandra Ramani, and Mr. Jogindersingh Gianchand Jaswal.
The acquisition was approved by the Board of Directors at a meeting held on Thursday, August 20, 2026. The price per share for this acquisition is ₹103.22, making the aggregate consideration ₹246.11 crore (Indian Rupees Two Hundred and Forty-Six Crores Eleven Lakhs Seventy-Seven Thousand Six Hundred and Eighty only).
As a consequence of acquiring control and voting rights exceeding 25% in Kronox Lab Sciences Limited, Indo Borax & Chemicals Limited, along with Zenrock Chemicals Private Limited, will make a mandatory open offer to the public shareholders of Kronox Lab Sciences Limited. This open offer will be for up to 95,70,000 equity shares, representing approximately 25.79% of the voting share capital, at a price to be determined according to SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011.
The acquisition is part of Indo Borax's long-term strategy to diversify its portfolio into sectors with stability and growth potential, aiming to nurture and expand Kronox Lab's business. The transaction is expected to be completed within three months of the public announcement. Kronox Lab Sciences Limited, incorporated in 2008, is engaged in manufacturing high purity specialty fine chemicals and is listed on both NSE and BSE. For the financial year 2025-26, Kronox Lab reported a turnover of ₹101.22 crore.
What to do with a filing like this
Indo Borax & Chemicals Limited filed this with the NSE as a statutory disclosure, categorised under acquisition. It is a primary document, not a recommendation, and the desk marks it high impact, which is the band that most often changes something.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Indo Borax & Chemicals Limited. Read the original for the full detail.